9 Analysts Have This To Say About Sangamo Therapeutics

9位分析师对Sangamo Therapeutics的看法

Benzinga · 2024/12/31 11:00

9 analysts have shared their evaluations of Sangamo Therapeutics (NASDAQ:SGMO) during the recent three months, expressing a mix of bullish and bearish perspectives.

在最近三个月，9位分析师对Sangamo Therapeutics（纳斯达克：SGMO）分享了他们的评估，表达了看好和看淡的混合观点。

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

下表提供了分析师最近评级的简明概述，提供了过去30天内情绪变化的洞察，并与前几个月进行了比较，以便全面了解。

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $7.89, a high estimate of $10.00, and a low estimate of $2.00. Observing a 16.37% increase, the current average has risen from the previous average price target of $6.78.

分析师通过对12个月价格目标的评估提供更深层的见解，显示出平均目标为7.89美元，最高预估为10.00美元，最低预估为2.00美元。观察到16.37%的增长，目前的平均值从之前的6.78美元的平均价格目标上升了。

Diving into Analyst Ratings...

深入探讨...

登录免费看全文

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

9 Analysts Have This To Say About Sangamo Therapeutics

9 Analysts Have This To Say About Sangamo Therapeutics

风险及免责提示

声明